{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"2"}]}],"title":"FGFR3 Non Responder"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"8"}]}],"title":"FGFR3 Responder"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Number of participants who are responders and nonresponders after 4 cycles of bortezomib, doxorubicin and dexamethasone (PAD) induction stratified by protein expression (FGFR3)","groups":[{"description":"Participants without FGFR3 expression","id":"OG000","title":"Negative"},{"description":"Participants with FGFR3 expression","id":"OG001","title":"Positive"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD. The ORR was imputed, with those who discontinued treatment or who had efficacy data unavailable being coded as Non-Responders.","reportingStatus":"POSTED","timeFrame":"84 days","title":"Overall Response Rate (ORR) Stratified by Protein Expression (FGFR3)","type":"SECONDARY","unitOfMeasure":"Participants"}